Isosorbide Mononitraat Retard Rph (Isosorbide Mononitrate)

After oral intake, isosorbide mononitrate is converted to nitric oxide, which relaxes vascular smooth muscle through the cyclic GMP pathway. This vasodilation lowers both preload and afterload, decreasing myocardial oxygen demand and relieving angina.

The specific dose and dosing schedule are determined by the prescribing clinician based on the patient’s condition, response, and tolerability. No standardized regimen is provided here.

Safety data for use in pregnancy and lactation are limited. The medication should only be used if the potential benefit justifies the potential risk to the fetus or infant, and decisions should be made by a qualified healthcare professional.

Submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Isosorbide mononitrate belongs to the nitrate class, offering sustained nitric‑oxide release. Compared with short‑acting nitrates, it provides more stable plasma levels and fewer dosing fluctuations, but it shares similar vasodilatory effects with agents such as nitroglycerin and may be used when those alternatives are unsuitable.

Store the tablets at room temperature, below 25 °C, in the original packaging. Keep them away from moisture, direct sunlight, and excessive heat to maintain product stability.

The medication is taken orally, usually as an extended‑release tablet, with or without food as directed by the prescriber. Swallow the tablet whole; do not crush or chew, as this can alter the release profile.

Serious risks include severe hypotension, syncope, and rare allergic reactions such as angioedema. Patients should seek immediate medical attention if they experience fainting, a sudden drop in blood pressure, or signs of a severe allergic response.

Individuals with known hypersensitivity to isosorbide mononitrate or other nitrates, those taking phosphodiesterase‑5 inhibitors, and patients with severe hypotension or recent myocardial infarction should avoid this medication unless specifically advised by a healthcare professional.